We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic Expands Panther Fusion's Menu With Diagnostic Innovation
Read MoreHide Full Article
Key Takeaways
Hologic gains FDA and CE approvals for its new Panther Fusion GI Bacterial and Expanded Assays.
Hologic's new assays use rapid molecular tech to detect common bacterial causes of gastroenteritis.
Panther Fusion's expanding menu strengthens Hologic's molecular diagnostics growth prospects.
Hologic (HOLX - Free Report) has highlighted the role of its Panther Fusion platform in supporting the future growth of its Diagnostics business. Fusion is an add-on module to the base Panther system, providing a broader and growing in vitro diagnostics menu and Open Access functionality to run laboratory-developed tests. Used mainly for respiratory testing, diversification of the menu has been on the cards to further reinforce the company’s presence in molecular labs. Building on this, Hologic recently announced dual regulatory nods for the Panther Fusion Gastrointestinal (“GI”) Bacterial and Expanded Bacterial Assays — the FDA’s 510(k) clearance and CE marking in the European Union in accordance with In Vitro Diagnostic Regulation (“IVDR”).
Pathogens causing severe diarrheal illness have traditionally required a combination of culture, biochemical and microscopy-based tests, which can be labor-intensive, time-consuming and less sensitive than molecular methods. In these situations, it is crucial for laboratories and clinicians worldwide to have access to tools that can provide rapid and timely informed care.
Hologic’s new GI pathogen detection tests use rapid molecular technology and cover common bacterial causes of infectious gastroenteritis, including Salmonella, Campylobacter and Shigella, and can be run together or in any combination. The assays’ customizable mini-panel format supports specific and tailored testing to individual patients’ needs, helping reduce testing, streamline lab processes, and speed up the time to diagnosis and clinical management.
This year, Panther Fusion is seeing strong traction among customers, aiding Molecular Diagnostics’ growth. With labs able to consolidate a growing menu of assays for women’s health, sexually transmitted infections, respiratory infections, viral load, transplant viruses, and now infectious gastroenteritis, it further reinforces the long-term prospects of this molecular diagnostics platform.
Updates From Hologic’s Diagnostics Peers
QIAGEN’s (QGEN - Free Report) full portfolio of QIAstat-Dx panels is now CE-IVDR certified for use in clinical syndromic testing. This includes an expanded Meningitis/Encephalitis Panel that marks a major advancement in the diagnosis of central nervous system infections. In addition, QIAGEN secured FDA clearance for the QIAstat-Dx Rise — a version of the QIAstat-Dx automated syndromic testing system that offers enhanced throughput with the easiest workflow available to global customers.
Myriad Genetics (MYGN - Free Report) has teamed up with AI technology company SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic test. The partnership will combine MYGN’s advanced laboratory capabilities in the United States to support global testing for clinical trials and SOPHiA GENETICS’ broad, decentralized network of more than 800 connected institutions in more than 70 countries for global test deployment. Further, a study demonstrated that Myriad Genetics’ molecular residual disease (MRD) test, Precise MRD, successfully delayed the initiation of systemic therapy in patients with oligometastatic clear-cell renal cell carcinoma.
HOLX Stock Performance, Valuation and Estimates
In the past six months, Hologic shares rose 14.2%, well above the industry’s 3.9% growth.
Image Source: Zacks Investment Research
Hologic is trading at a forward five-year price-to-earnings of 15.07X, lower than the industry average of 28.28X. The stock carries a Value Score of B at present.
Image Source: Zacks Investment Research
See how analysts are projecting Hologic’s fiscal 2025 earnings.
Image: Bigstock
Hologic Expands Panther Fusion's Menu With Diagnostic Innovation
Key Takeaways
Hologic (HOLX - Free Report) has highlighted the role of its Panther Fusion platform in supporting the future growth of its Diagnostics business. Fusion is an add-on module to the base Panther system, providing a broader and growing in vitro diagnostics menu and Open Access functionality to run laboratory-developed tests. Used mainly for respiratory testing, diversification of the menu has been on the cards to further reinforce the company’s presence in molecular labs. Building on this, Hologic recently announced dual regulatory nods for the Panther Fusion Gastrointestinal (“GI”) Bacterial and Expanded Bacterial Assays — the FDA’s 510(k) clearance and CE marking in the European Union in accordance with In Vitro Diagnostic Regulation (“IVDR”).
Pathogens causing severe diarrheal illness have traditionally required a combination of culture, biochemical and microscopy-based tests, which can be labor-intensive, time-consuming and less sensitive than molecular methods. In these situations, it is crucial for laboratories and clinicians worldwide to have access to tools that can provide rapid and timely informed care.
Hologic’s new GI pathogen detection tests use rapid molecular technology and cover common bacterial causes of infectious gastroenteritis, including Salmonella, Campylobacter and Shigella, and can be run together or in any combination. The assays’ customizable mini-panel format supports specific and tailored testing to individual patients’ needs, helping reduce testing, streamline lab processes, and speed up the time to diagnosis and clinical management.
This year, Panther Fusion is seeing strong traction among customers, aiding Molecular Diagnostics’ growth. With labs able to consolidate a growing menu of assays for women’s health, sexually transmitted infections, respiratory infections, viral load, transplant viruses, and now infectious gastroenteritis, it further reinforces the long-term prospects of this molecular diagnostics platform.
Updates From Hologic’s Diagnostics Peers
QIAGEN’s (QGEN - Free Report) full portfolio of QIAstat-Dx panels is now CE-IVDR certified for use in clinical syndromic testing. This includes an expanded Meningitis/Encephalitis Panel that marks a major advancement in the diagnosis of central nervous system infections. In addition, QIAGEN secured FDA clearance for the QIAstat-Dx Rise — a version of the QIAstat-Dx automated syndromic testing system that offers enhanced throughput with the easiest workflow available to global customers.
Myriad Genetics (MYGN - Free Report) has teamed up with AI technology company SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic test. The partnership will combine MYGN’s advanced laboratory capabilities in the United States to support global testing for clinical trials and SOPHiA GENETICS’ broad, decentralized network of more than 800 connected institutions in more than 70 countries for global test deployment. Further, a study demonstrated that Myriad Genetics’ molecular residual disease (MRD) test, Precise MRD, successfully delayed the initiation of systemic therapy in patients with oligometastatic clear-cell renal cell carcinoma.
HOLX Stock Performance, Valuation and Estimates
In the past six months, Hologic shares rose 14.2%, well above the industry’s 3.9% growth.
Image Source: Zacks Investment Research
Hologic is trading at a forward five-year price-to-earnings of 15.07X, lower than the industry average of 28.28X. The stock carries a Value Score of B at present.
Image Source: Zacks Investment Research
See how analysts are projecting Hologic’s fiscal 2025 earnings.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.